证券之星消息，截至2025年11月14日收盘，天臣医疗(688013)报收于56.0元，下跌2.12%，换手率 1.77%，成交量1.44万手，成交额8138.62万元。 | 指标 | 天臣医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 45.45 乙元 | 116.39亿元 | 78 124 | | 净资产 | 6亿元 | 38.93亿元 | 115 124 | | 净利润 | 7194.58万元 | 2.12亿元 | 57 124 | | 市盈率(动) | 47.38 | 58.18 | 53 124 | | 市净率 | 7.58 | 4.14 | 113 124 | | 毛利率 | 63.22% | 51.22% | 43 124 | | 净利率 | 29.51% | 9.57% | 15 124 | | ROE | 12.52% | 0.15% | 9 124 | 天臣医疗2025年三季报显示，前三季度公司主营收入2.44亿元，同比上升20.66%；归母净利润7194.58 万元，同比上升68.29%；扣非净利润6620.23万元，同比 ...

截至发稿，美康生物市值为42亿元。 2024年1至12月份，美康生物的营业收入构成为：医疗器械占比100.0%。 （记者 王瀚黎） 每经AI快讯，美康生物（SZ 300439，收盘价：11.04元）11月14日晚间发布公告称，公司第五届第十七 次董事会会议于2025年11月14日在公司会议室以现场表决的方式召开。会议审议了《关于补选公司第五 届董事会审计委员会委员的议案》等文件。 每经头条（nbdtoutiao）——展望"十五五"|专访财科院院长杨志勇：遏制地方政府新增隐性债务，债务 信息要透明，尽可能降低利息成本 ...

核心观点 简评 Q3 业绩符合预期，海外市场高增长，利润波动与费用增加有关2025 年前三季度，公司营收、归母净利 润、扣非归母净利润分别为8.08、1.80、1.40 亿元，分别同比增长34.24%、43.87%和63.41%；2025Q3 营收、归母净利润和扣非归母净利润分别为2.64、0.49 和0.40 亿元，分别同比增长20.22%、48.61%和 112.64%，环比增速分别为-5.09%、-18.09%、+3.21%，业绩符合预期。25Q3 利润增速高于收入增速， 主要系毛利率提升和费用率下降所致。 Q3 业绩符合预期，海外市场高增长，利润波动与费用增加有关。 展望Q4，公司收入有望加速增长，利润在低基数下有望实现高增长。 公司无降噪棉呼吸机新品自7 月开始已经批量进入美国市场， 四季度有望加速放量；在欧洲市场，公司 已基本完成云平台建设，通过本土化运营策略，公司产品开始进入主流医保市场；在国内市场，公司9 月底启动线上经销向直销模式切换，第三季度处于模式转换初期，预计第四季度新模式开始增厚业绩。 事件 公司发布2025 年三季报 2025 年前三季度，公司营收、归母净利润、扣非归母净利润分别为 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 恩威医药(301331.SZ)公告称，公司作为有限合伙人以自有资金认缴出资2000万元，参与设立嘉兴磐霖 嘉颐创业投资合伙企业（有限合伙）。该基金规模为20100万元，投资方向包括医疗（创新药、创新医 疗器械）及科技（企业级服务、硬科技）等。合伙企业尚需完成中国证券投资基金业协会备案和工商变 更登记手续，实施过程存在不确定性。公司本次投资可能面临较长的投资回报期，以及投资项目不能实 现预期收益或投资失败的风险。 ...

上海银行现场解读相关金融服务政策，为企业提供多元化融资方案支持。自由交流中，投资机构与企业代表就技术创新、市场应用及发展前景等话题展开 讨论。 路演环节，四家Medpark企业的创新项目依次登台亮相。 11月14日，Medpark十一月首场投融资对接会在江苏医疗器械科技产业园加速器顺利举行。会议邀请了多家投资机构与银行代表参会，为园内创新企业搭 建高效的产融对接平台。 自今年8月以来，Medpark已连续举办多场月度投融资对接活动，形成常态化服务机制。下一步，Medpark将在现有服务基础上，持续深化投融资对接效 能，促进资本、技术、人才等创新要素加速集聚，为区域医疗器械及大健康产业创新发展注入动能。 苏州小闯医疗科技有限公司是一家专注于十二指肠PFA消融的创新企业；苏州华超医疗科技有限公司在研的泌尿系统蒸汽消融技术处于行业领先水平；苏 州国科康成医疗科技有限公司致力于AI影像辅助诊疗的研究；苏州海思临科医学科技有限公司专注于精准诊断，业务涵盖医疗机器人、人工智能设备的 研发制造与诊疗平台的数据分析处理等。 ...

Group 1 - Huasheng Lithium Electric reports no significant changes in production and operations, but faces risks of performance decline or losses due to uncertainties in the lithium battery industry and ongoing cost reduction efforts [3] - Shapuaisi has received approval from the National Medical Products Administration for clinical trials of deoxycorticosterone ketone acid solution, aimed at maintaining pupil dilation during cataract surgery [4] - Obit Zhongguang has completed over 10 chip tape-outs, including iToF, dToF sensing chips, and dedicated ASIC computing chips, enhancing its 3D vision perception technology [5] Group 2 - Lio Co. has provided a joint liability guarantee of 420 million yuan for its wholly-owned subsidiary, Zhejiang Pump Industry, with a maximum balance of 420 million yuan [6] - Hanchuan Intelligent's controlling shareholder will have 2.67% of shares judicially auctioned, potentially reducing their stake to 19.72% if all shares are sold [7] - Tianqi Mould plans to cash-step acquire 50% of Dongshi shares, which would make Dongshi a subsidiary, pending further negotiations and due diligence [8] Group 3 - Wowo Bio has decided to terminate the research project for the smoke mold puncture solution and will not proceed with further clinical trials [9] - Aerospace Electromechanical's wholly-owned subsidiary has received arbitration support for a claim amounting to approximately 19.17 billion Korean won [10][11] - Changyuan Power's subsidiary has received approval for a 100MW wind power project, with a total dynamic investment of 583 million yuan [12] Group 4 - Tianma Technology reported an output of approximately 1732.99 tons of eels in October 2025, with a sales price range of 55,000 to 100,000 yuan per ton [14] - China State Construction signed new contracts worth 3.61 trillion yuan from January to October 2025, reflecting a year-on-year growth of 1% [15] - Gansu Expressway reported vehicle toll service revenue of 266 million yuan in October 2025 [16] Group 5 - China Metallurgical Group signed new contracts totaling 845.07 billion yuan from January to October 2025, a decrease of 11.8% year-on-year [17] - China Coal Energy reported a coal sales volume of 21.88 million tons in October 2025, down 12.8% year-on-year [18] - Shanghai Airport's Pudong International Airport saw a 12.46% year-on-year increase in passenger throughput in October 2025 [19] Group 6 - China Shenhua reported a coal production of 26.4 million tons in October 2025, a decrease of 7.4% year-on-year [20] - Camel Group's chairman plans to reduce his stake by 0.6137% due to personal financial needs [22] - Qingyuan Co. issued 5 million convertible bonds, with the controlling shareholder reducing 13.71% of the bonds [24]

Core Insights - The appointment of Aldo Denti to Imricor Medical Systems signifies a strategic shift in the medical technology landscape, particularly as Johnson & Johnson is in the process of spinning off its orthopedic business [2][3][5] - Johnson & Johnson's decision to separate its DePuy Synthes orthopedic division is part of a broader restructuring strategy aimed at focusing on high-growth areas such as oncology, immunology, and cardiovascular health [3][4][10] - The migration of experienced leaders like Denti from orthopedic to cardiac intervention reflects a trend of knowledge and resource redistribution within the industry, as companies seek to innovate in new technological domains [6][9][12] Group 1: Corporate Restructuring - Johnson & Johnson announced plans to spin off its DePuy Synthes orthopedic business, which generates approximately $9.2 billion in annual revenue, representing about 10% of the company's total revenue [3][4] - The spin-off is expected to be completed within 18 to 24 months, with a target for the new entity to be operational by mid-2027 [3] - This restructuring follows the earlier divestment of its consumer health business, Kenvue, indicating a strategic pivot towards six high-growth sectors [3][10] Group 2: Talent Migration - Aldo Denti's transition from Johnson & Johnson to Imricor exemplifies the movement of talent from traditional orthopedic sectors to emerging fields like cardiac intervention [6][9] - Denti's extensive experience in orthopedic management and innovation positions him as a valuable asset for Imricor, which focuses on MRI-guided electrophysiological procedures [8][12] - The shift in leadership reflects a broader trend where expertise in surgical engineering and global business is becoming a scarce resource in new technology companies [9][12] Group 3: Technological and Growth Logic - The healthcare technology sector is witnessing a shift from mechanical and material innovations to advancements in soft tissue, neural systems, and minimally invasive interventions [9][10] - Companies like Imricor are at a critical juncture, moving from research validation to global commercialization, with Denti's role expected to enhance market access and clinical education [12] - The overarching narrative suggests that the future of medical technology will be defined more by technological logic than by product lines, as the industry transitions from orthopedic to cardiac and from mechanical to intelligent solutions [13][14]

Core Insights - Foshan Ruosen Medical Equipment Co., Ltd. has been established with a registered capital of 100,000 RMB and is led by legal representative Shen Danrong [1] Company Overview - The company is engaged in the production and sales of Class I and Class II medical devices, as well as the wholesale of protective equipment for medical personnel [1] - It also offers software development, manufacturing of computer hardware and peripherals, and internet sales excluding licensed products [1] - The company is authorized to conduct various technical services, including development, consulting, and transfer [1] Licensing and Regulatory Compliance - The company is permitted to produce and operate Class II and Class III medical devices, as well as engage in the import and export of state-managed trade goods [1] - Medical device internet information services are also included in its licensed activities, which require approval from relevant authorities before commencement [1]

天臣医疗（688013.SH）11月14日在投资者互动平台表示，尊敬的投资者，您好！公司正在研发的集约 式智能手术平台及执行末端（MA）项目正按计划有序推进中，目前已完成生产线的工艺验证，正在进 行严格的产品各项技术性能验证，关于项目后续进展情况，公司将按相关法律法规要求及时履行信息披 露义务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司的MA项目进展如何，预期何时可以开始医疗 器械注册申报？ ...

Core Viewpoint - The company is proactively reducing the price of its KHA130 blood perfusion device to 339 yuan starting from September 2025 to fulfill social responsibility and respond to market competition [1] Group 1: Pricing Strategy - The price reduction for the KHA130 blood perfusion device will be implemented across various provinces, with the specific timing dependent on local platforms [1] - The KHA130 accounted for 5.22% of the company's revenue in the first three quarters of 2025 [1] Group 2: Financial Impact - The price reduction initiative has not significantly affected the company's overall gross margin to date [1] - Future impacts on financial performance will depend on the effectiveness of market promotion efforts, with updates to be disclosed in regular reports [1]